The 2025 USP Drug Shortages Report has been released, and it highlights a troubling trend: discontinuations of essential, life-saving medicines continue to rise.
In 2025, drug product discontinuations increased by 60%, reaching the highest annual total in 5 years. Drug shortages are often driven by single points of failure; medicines that are manufactured at only one facility or place in the world. When products are discontinued, the market becomes even more concentrated, leaving patients with fewer treatment options and fewer backup sources when disruptions occur.
Drug discontinuations rose 60% in 2025, reaching the highest number of discontinued drug products recorded since 2019
Building a more resilient healthcare supply chain requires greater redundancy, diversified manufacturing, back-up plans, and sustained investment in securing our supply chain. We must do more to ensure patients have reliable access to the medicines they depend on.
Thank you to USP for this important and timely report. We are proud to support this work as a member of the Drug Shortage Task Force, the Resiliency Center Board, and the USP Convention.
Read the full Drug Shortages Report: https://bit.ly/4dZW4eZ
